JPMorgan Chase & Co. purchased a new stake in Clearside Biomedical, Inc. (NASDAQ:CLSD) during the first quarter, according to its most recent 13F filing with the SEC. The fund purchased 22,420 shares of the company’s stock, valued at approximately $178,000. JPMorgan Chase & Co. owned 0.09% of Clearside Biomedical as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in CLSD. Granite Investment Partners LLC purchased a new stake in Clearside Biomedical during the first quarter valued at about $423,000. Norges Bank bought a new stake in Clearside Biomedical during the fourth quarter valued at $417,000. Wells Fargo & Company MN increased its stake in Clearside Biomedical by 325.0% in the first quarter. Wells Fargo & Company MN now owns 16,739 shares of the company’s stock valued at $133,000 after buying an additional 12,800 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Clearside Biomedical by 10.8% in the first quarter. Bank of New York Mellon Corp now owns 34,823 shares of the company’s stock valued at $277,000 after buying an additional 3,404 shares during the last quarter. 49.67% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Clearside Biomedical, Inc. (NASDAQ CLSD) opened at 8.00 on Tuesday. The company’s market cap is $202.40 million. The company’s 50 day moving average is $9.15 and its 200-day moving average is $8.05. Clearside Biomedical, Inc. has a 12 month low of $5.44 and a 12 month high of $25.08.
Clearside Biomedical (NASDAQ:CLSD) last announced its quarterly earnings data on Wednesday, May 10th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.03. Clearside Biomedical had a negative net margin of 154,030.02% and a negative return on equity of 53.20%. The company had revenue of $0.01 million during the quarter. Analysts expect that Clearside Biomedical, Inc. will post ($1.72) EPS for the current fiscal year.
WARNING: This piece was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.themarketsdaily.com/2017/08/08/jpmorgan-chase-co-takes-position-in-clearside-biomedical-inc-clsd.html.
CLSD has been the subject of several research analyst reports. Cowen and Company reissued a “buy” rating on shares of Clearside Biomedical in a research report on Thursday, June 8th. Zacks Investment Research raised shares of Clearside Biomedical from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a research report on Tuesday, July 11th. ValuEngine raised shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. JMP Securities initiated coverage on shares of Clearside Biomedical in a research report on Thursday, May 25th. They issued an “outperform” rating and a $21.00 target price for the company. Finally, Wedbush reissued an “outperform” rating and issued a $27.00 target price on shares of Clearside Biomedical in a research report on Thursday, April 20th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $19.00.
In other news, insider Daniel H. White sold 8,000 shares of the stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $8.41, for a total value of $67,280.00. Following the completion of the transaction, the insider now owns 511,267 shares in the company, valued at approximately $4,299,755.47. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Daniel H. White sold 3,600 shares of the stock in a transaction on Tuesday, June 13th. The shares were sold at an average price of $7.78, for a total transaction of $28,008.00. Following the completion of the transaction, the chief executive officer now owns 504,067 shares of the company’s stock, valued at approximately $3,921,641.26. The disclosure for this sale can be found here. In the last 90 days, insiders sold 125,170 shares of company stock valued at $1,080,884. Corporate insiders own 20.90% of the company’s stock.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.
Want to see what other hedge funds are holding CLSD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clearside Biomedical, Inc. (NASDAQ:CLSD).
Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.